Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Table 1 Characteristics of children with urinary tract infection caused by E. coli or K. pneumoniae

Factor	Non-ESBL group	ESBL group	p-value
Factor	(n = 189)	(n = 22)	p-value
Sex (male)	114 (60.3)	14 (63.6)	0.763
Age (months)	4.0 (3.0–7.0)	5.0 (4.0–6.5)	0.203
Pathogen			0.543
E. coli	183 (96.8)	21 (95.5)
K. pneumoniae	6 (3.2)	1 (4.5)
Methods of urine collection			0.119
Urine bag	174 (92.1)	18 (81.8)
Mid-stream urine	15 (7.9)	4 (18.2)
Previous history of urinary tract infection	9 (4.8)	1 (4.5)	1.000
Fever duration at the beginning of antibiotic therapy (days)^a	2.0 (1.0-3.0)	2.0 (1.0-3.0)	0.923
Acute pyelonephritis on DMSA scan^b	127 (80.4)	17 (81.0)	1.000
Vesicoureteral reflux on VCUG^c	18 (15.9)	4 (23.5)	0.488

Data are median (interquartile range) or no. (%) of cases
ESBL extended-spectrum β-lactamase; DMSA ^99mtechnetium dimercaptosuccinic acid; VCUG voiding cystoutrthrography
^aThe accurate duration of fever at the beginning of antibiotic therapy was not determined in one child in the non-ESBL group, who was treated in the outpatient clinic
^bDMSA scan was performed in 179 children (158 in the non-ESBL group, 21 in the ESBL group)
^cVCUG was performed in 130 children (113 in the non-ESBL group, 17 in the ESBL group)

ISSN: 1471-2334